Department of Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Hepatocellular Carcinoma 74%
3. Non-Small Cell Lung Carcinoma 71%
4. Survival 59%
5. Lung Neoplasms 50%
6. Adenocarcinoma of Lung 47%
7. Drug Therapy 46%
8. ErbB Receptors 42%
9. ramucirumab 41%
10. Therapeutics 39%
11. Mutation 38%
12. Colorectal Neoplasms 35%
13. Head and Neck Neoplasms 34%
14. Squamous Cell Carcinoma 32%
15. Safety 30%
16. Protein-Tyrosine Kinases 29%
17. Sorafenib 29%
18. Platinum 27%
19. Nasopharyngeal Carcinoma 27%
20. Tubulin 25%
21. osimertinib 24%
22. Cell Line 24%
23. pembrolizumab 23%
24. KB Cells 23%
25. Leucovorin 22%
26. Fluorouracil 21%
27. Antineoplastic Agents 21%
28. Afatinib 20%
29. Genes 20%
30. gemcitabine 20%
31. Inhibitory Concentration 50 20%
32. Squamous Cell Carcinoma of Head and Neck 20%
33. Placebos 19%
34. Confidence Intervals 19%
35. Paclitaxel 19%
36. Down-Regulation 18%
37. Microtubules 18%
38. Erlotinib Hydrochloride 18%
39. Growth 18%
40. Stomach Neoplasms 18%
41. Antimitotic Agents 17%
42. Biomarkers 17%
43. Proteins 17%
44. Tubulin Modulators 17%
45. Radiotherapy 17%
46. MicroRNAs 16%
47. Smoking 16%
48. Adenocarcinoma 16%
49. Mouth Neoplasms 15%
50. Gefitinib 15%
51. Pancreatic Neoplasms 15%
52. DNA 14%
53. Genome-Wide Association Study 14%
54. Copper Transporter 1 14%
55. cathepsin S 14%
56. Hepatitis B virus 14%
57. Type II DNA Topoisomerase 13%
58. Nanoparticles 13%
59. Ligands 13%
60. fosbretabulin 13%
61. Irinotecan 13%
62. Drug Resistance 12%
63. Lung 12%
64. Chemoradiotherapy 12%
65. Colchicine 12%
66. Carcinogenesis 11%
67. Pharmaceutical Preparations 11%
68. Malignant Pleural Effusion 11%
69. In Vitro Techniques 11%
70. Quality of Life 11%
71. alpha-Fetoproteins 11%
72. Cetuximab 11%
73. Stomach 11%
74. Carcinoma 11%
75. Liver 10%
76. Pharmacokinetics 10%
77. Polymerization 10%
78. Population 10%
79. Human Activities 10%
80. Nasopharyngeal Neoplasms 10%
81. 4'-demethylepipodophyllotoxin 10%
82. Argininosuccinate Synthase 10%
83. Liver Neoplasms 10%
84. Smokers 9%
85. Cell Movement 9%
86. Nivolumab 9%
87. Heterografts 9%